The estimated Net Worth of Capital (Gp), Llcbaker Juli... is at least $52.9 Million dollars as of 7 March 2012. Capital Juli owns over 1,099 units of Seagen Inc stock worth over $52,143,462 and over the last 20 years Capital sold SGEN stock worth over $724,110.
Capital has made over 32 trades of the Seagen Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently Capital bought 1,099 units of SGEN stock worth $33,091 on 7 March 2012.
The largest trade Capital's ever made was buying 51,270 units of Seagen Inc stock on 29 November 2011 worth over $668,561. On average, Capital trades about 4,735 units every 19 days since 2005. As of 7 March 2012 Capital still owns at least 227,840 units of Seagen Inc stock.
You can see the complete history of Capital Juli stock trades at the bottom of the page.
Over the last 22 years, insiders at Seagen Inc have traded over $729,924,224 worth of Seagen Inc stock and bought 35,347,908 units worth $1,433,871,526 . The most active insiders traders include Bros. Advisors Lp667, L.P.B..., Felixbaker Julian Baker Bro..., and Brothers Life Sciences Capi.... On average, Seagen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $18,157,295. The most recent stock trade was executed by David R Epstein on 10 November 2023, trading 10,620 units of SGEN stock currently worth $2,262,166.
seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys
Seagen Inc executives and other stock owners filed with the SEC include: